Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy

Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy

Background: Interleukin (IL) inhibitors achieve greater levels of efficacy than older systemic therapies. We calculated the number needed to treat (NNT) of ixekizumab compared with other IL inhibitors approved in Italy for the treatment of moderate-to-severe plaque psoriasis. Methods: The clinical...

Full description

Bibliographic Details
Main Authors: Roberto Ravasio, Antonio Costanzo, Silvia Antonelli, Alessia Maiorino, Serena Losi
Format: Article
Language:English
Published: AboutScience Srl 2021-04-01
Series:Global & Regional Health Technology Assessment
Subjects:
Interleukin inhibitor
Ixekizumab
Number needed to treat
Plaque psoriasis
Online Access:https://journals.aboutscience.eu/index.php/grhta/article/view/2222

Internet

https://journals.aboutscience.eu/index.php/grhta/article/view/2222

Similar Items